Table 1

Clinical characteristics

Control donor subjects (n=10)IPF patients (n=10)HP-associated IPF (n=9)P value
Age (year), mean (SD)58.5 (9.7)60.2 (8.2)62.4 (10.3)NS
Sex (male/female)8/27/37/2
 Never smoked/
 Pack-year (range)21 (0–32)24.2 (6–35)29 (9–38)NS
FEV1, pred, mean (SD)ND72.1 (16.8)75.4 (14.2)NS
FVC, % pred, mean (SD)ND71.8 (8.5)68.3 (7.8)NS
TLC, % pred, mean (SD)ND71.5 (12.1)62.6 (13.4)NS
DLco, % pred, mean (SD)ND47.1 (11.5)39.5 (13.4)NS
Ground glass %,
mean (SD)
022.4 (14.2)31.2 (8.5)<0.001*
Honeycombing %,
mean (SD)
024.5 (12.4)32.5 (7.4)<0.001*
PaO2, mm Hg, mean (SD)93.5 (4.2)62.4 (8.5)52.2 (8.9)<0.001*
mPAP mm Hg/L/min, mean (SD)ND19.4 (3.5)47.4 (6.7)<0.01†
NAC (y/n)0/104/61/8
Pirfenidone (y/n)0/106/44/5
  • *Compared with control donors.

  • †Compared with patients with IPF.

  • Data are means (SD). N-acetyl-l-cysteine (NAC)/pirfenidone refers to patients who received this treatment at the time of pulmonary biopsy.

  • % pred, % predicted; DLco, diffusion capacity of the lung for carbon monoxide; mPAP, mean pulmonary arterial pressure; ND, not determined; NS, not significance between groups (P >0.05); pack-year, 1 year of smoking 20 cigarettes per day; PaO2, arterial blood oxygen pressure; TLC, total lung capacity; ground glass %, % of pulmonary parenchyma with ground glass on a CT image; honeycombing %, % of pulmonary parenchyma with honeycombing on a CT image.